Neonatal sepsis (NS) is regarded as one of the most common causes of morbidity and mortality among neonates worldwide. However, the magnitude of the problem is higher in low income countries, in spite of recent improvement of neonatal health care units. Accurate and early diagnosis of NS is the corner stone toward better therapeutic approach and safe outcome. Creactive protein is currently used however it has been reported to have a low specificity and to rise in blood of cases with a delay of 24 hours than other biomarkers like inerleukin-16 or procalcitonin. Therefore, identification of new biomarkers with high specificity and sensitivity is extremely needed. The current study aimed to detect changes in miR-146a serum expression levels among NS cases, neonates at high risk to develop sepsis and healthy control neonates and to assess the value of serum miR-146a as early indicator of NS. qPCR was used for detection of miR-146a serum expression among different study groups. Serum miR-146a showed differential expression of statistical significance within study groups, with the highest level in NS group and the lowest in healthy controls. Moreover, serum miR-146a showed a significant positive correlation with the CRP titer in NS group. Receiver operating characteristic (ROC) curve analysis revealed that best cut off value for miR-146a was at 0.539 relative units, with a sensitivity of 91.7%, specificity of 100% and 95.7% accuracy. As regard to CRP, the best ROC curve was at 18 mg/dL with 100% sensitivity, 86.4% specificity and 93.5% accuracy. Combination of miR-146a and CRP increased specificity, sensitivity and accuracy to 100%. Furthermore, in multivariate logistic regression analysis, only CRP and miR-146a were considered as independent risk factor for prediction of sepsis within high risk neonates. In conclusion, serum miR-146a may be a promising predictor for sepsis within the high risk neonates. However, large-scale prospective studies are required to confirm our findings. . 
Introduction
Neonatal sepsis is defined as systemic inflammatory response syndrome (SIRS) Despite the advances in neonatal health care, a recent study reported that the total mortality rate for the proven neonatal sepsis in Egypt, was 51%.
Importantly, the NS survivors are at high risk for neurological and developmental morbidity (3).
Early diagnosis of NS and efficient therapeutic approach may help to improve the prognosis and outcome of NS cases. However early identification of NS is a great challenge due to the nonspecific clinical presentations. So far, blood culture is the main laboratory confirmatory test, however, it is a time-consuming procedure and its results may be affected by antibiotic administration. Moreover, acute phase reactants as C-reactive protein (CRP) and cytokines lack the ability to specifically differentiate between NS and SIRS or other inflammatory diseases. In addition, CRP plasma level increases with a lag of 24 hours after cytokines and procalcitonin (4, 5).
On the other hand, initiation of empirical antibiotic treatment once NS is suspected, increases the risk of development of multidrug resistant pathogens MiR-146a is a member of the miR-146a miRNA family, it plays an important role in regulating inflammatory responses via a negative feedback pathway. MiR-146a is differentially expressed in several inflammatory, autoimmune diseases, viral infections and cancer. Therefore, previous studies suggested its use as a biomarker for diagnostic, prophylactic and therapeutic purposes(9).
The current study aimed to detect changes in gene expression level of serum miR-146a in NS cases, newborn at high risk to develop sepsis and healthy control neonates, to assess its potential use as indicator for early diagnosis of neonatal sepsis.
Subjects and Methods
The current study was conducted after approval of the study scheme by the ethical committee of 
Sampling:
Peripheral blood samples (3 ml) were withdrawn from the neonates during collection of first blood cultures and divided into 2 parts. The first part (1ml) was collected in EDTA tubes for CBC, performed by automated hematology analyzer Sysmex XS-1000i (Sysmex, Japan). The second part (2 ml) was collected into sterile vacutainers, allowed to clot, then serum was separated by centrifugation at room temperature for 10 minutes at 2,000 xg. The separated sera were used for CRP titer detection using latex agglutination (CRPLatex Cromatest) (10) and the remaining were stored at -80ºC for later miRNA isolation.
Isolation of total RNA including miRNA:
miRNeasy Serum/Plasma Kit (Qiagen, Germany)
was used according to the manufacturer's instructions to separate total RNA including miRNA from serum samples. 
Statistical analysis
The collected data were tabulated and analyzed 
Results
The current study included 24 neonates who were diagnosed as proved sepsis, they were 12 (50%) males and 12 (50%) were Coagulase-Negative Staphylococci (CoNS) and 2 (8.3%) were staph aureus).
As regards miR-146a expression, it showed significant differences between the studied groups. (Table 3) .
Discussion
The present study revealed a statistically significant increase in miR-146a serum expression level among proved sepsis group and high risk group neonates, as compared with healthy controls.
In addition, miR-146a expression in sera of neonates with proved sepsis was significantly higher than in sera of the high-risk group neonates.
These findings support previously reported results regarding upregulation of plasma miR-146a and miR-223 levels in children sepsis as compared with
SIRS and control groups (12).
In In this regard, these results agree with those of a former study on pediatric sepsis which showed that AUC of miR-146a was 0.815 and concluded that miR-146a may be a potential marker for early diagnosis of sepsis(12) . In another study conducted on sepsis versus SIRS patients, miR-146a predicted sepsis with AUC of 0.813, 60% sensitivity and specificity of 87.5%. They also suggested the use of miR-146a as a marker to differentiate sepsis from SIRS (23).
Furthermore, ROC curve analysis of CRP at cutoff value of 18 mg/dL showed 100% sensitivity, 86.4% specificity and accuracy of 93.5%. Importantly, the current study showed that, combination of both parameters, miR-146a and CRP increased the sensitivity, specificity and accuracy to 100%.
However, a recent meta-analysis revealed that CRP had limited sensitivity (0.75) and specificity (0.67) to point out sepsis (8). Therefore, currently CRP is not recommended in guidelines as a biomarker for sepsis (8, 24). Such discrepancy of results may be attributed to the difference in sample size.
Furthermore, the current study showed that only miR-146a and CRP were independent risk factors for prediction of sepsis within high risk neonates.
This results suggest that miRNA may be promising 
